Vinblastine-associated pulmonary toxicity in patients receiving combination therapy with mitomycin and cisplatin

Drug Intell Clin Pharm. 1986 Apr;20(4):287-9. doi: 10.1177/106002808602000415.

Abstract

Two of 33 patients entered in a local pilot study of mitomycin, vinblastine, and cisplatin for non-small cell lung cancer developed vinblastine-associated pulmonary toxicity. As with other reports of vinca alkaloid-related pulmonary toxicity, the regimen included mitomycin. Based on these cases and others previously reported, the incidence of abrupt pulmonary toxicity following vinca alkaloid administration as part of mitomycin/vinca alkaloid combination appears to be three to six percent. Suggestions for management are given.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / drug therapy
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carcinoma, Squamous Cell / drug therapy
  • Cisplatin / administration & dosage
  • Cisplatin / adverse effects
  • Humans
  • Lung Neoplasms / drug therapy
  • Male
  • Middle Aged
  • Mitomycins / administration & dosage
  • Mitomycins / adverse effects
  • Pilot Projects
  • Pneumonia / chemically induced*
  • Vinblastine / administration & dosage
  • Vinblastine / adverse effects

Substances

  • Mitomycins
  • Vinblastine
  • Cisplatin

Supplementary concepts

  • MVP protocol 2